Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice.

Approximately 15–40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS metastases, owing to the low levels of the drug re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Jing, Wu, Di, Qin, Meng, Liu, Chaoyong, Wang, Lan, Xu, Duo, Vinters, Harry V., Liu, Yang, Kranz, Emiko, Guan, Xin, Sun, Guibo, Sun, Xiaobo, Lee, YooJin, Martinez-Maza, Otoniel, Widney, Daniel, Lu, Yunfeng, Chen, Irvin SY., Kamata, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736720/
https://www.ncbi.nlm.nih.gov/pubmed/31384008
http://dx.doi.org/10.1038/s41551-019-0434-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736720/
https://www.ncbi.nlm.nih.gov/pubmed/31384008
http://dx.doi.org/10.1038/s41551-019-0434-z

Ejemplares similares